| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4247870 | Radiologic Clinics of North America | 2007 | 8 Pages |
Abstract
Within recent years, F-18 fluorodeoxyglucose (FDG) PET has become the most important nuclear medicine and radiology imaging modality in the management of lymphoma. FDG-PET detects more disease sites and involved organs than conventional staging procedures, including CT, and has a large influence on staging. FDG-PET performed during and after therapy seems to provide considerable prognostic information. The impact on patient outcome is not clear, however, because no controlled trials have yet been conducted and follow-up periods are generally short.
Related Topics
Health Sciences
Medicine and Dentistry
Radiology and Imaging
Authors
Donald A. MD, Homer A. MD,